These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 22871992)
1. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Cozzi SJ; Le TT; Ogbourne SM; James C; Suhrbier A Arch Dermatol Res; 2013 Jan; 305(1):79-83. PubMed ID: 22871992 [TBL] [Abstract][Full Text] [Related]
2. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer. Erlendsson AM Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209 [TBL] [Abstract][Full Text] [Related]
3. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. Berman B; Nestor MS; Newburger J; Park H; Swenson N J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702 [TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365 [TBL] [Abstract][Full Text] [Related]
5. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. Cozzi SJ; Ogbourne SM; James C; Rebel HG; de Gruijl FR; Ferguson B; Gardner J; Lee TT; Larcher T; Suhrbier A J Invest Dermatol; 2012 Apr; 132(4):1263-71. PubMed ID: 22189786 [TBL] [Abstract][Full Text] [Related]
7. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. Stahlhut M; Bertelsen M; Hoyer-Hansen M; Svendsen N; Eriksson AH; Lord JM; Scheel-Toellner D; Young SP; Zibert JR J Drugs Dermatol; 2012 Oct; 11(10):1181-92. PubMed ID: 23134983 [TBL] [Abstract][Full Text] [Related]
8. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. Gupta AK; Paquet M J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300 [TBL] [Abstract][Full Text] [Related]
9. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma. García-de-la-Fuente MR; Santacana M; Verdaguer J; Vilardell F; Garí E; Casanova JM Australas J Dermatol; 2020 May; 61(2):e200-e207. PubMed ID: 31944277 [TBL] [Abstract][Full Text] [Related]
10. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Keating GM Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025 [TBL] [Abstract][Full Text] [Related]
11. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization. Kostovic K; Gulin SJ; Mokos ZB; Ceovic R Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis. Stockfleth E; Bastian M Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409 [TBL] [Abstract][Full Text] [Related]
13. [Rapidly growing squamous cell carcinoma after ingenol mebutate treatment]. Ehret M; Velter C; Tebacher M; Bruant-Rodier C; Cribier B Ann Dermatol Venereol; 2018 Oct; 145(10):607-612. PubMed ID: 29779859 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119 [TBL] [Abstract][Full Text] [Related]
15. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. Rosen RH; Gupta AK; Tyring SK J Am Acad Dermatol; 2012 Mar; 66(3):486-93. PubMed ID: 22055282 [TBL] [Abstract][Full Text] [Related]
16. Ingenol Mebutate as Treatment of Squamous Cell Carcinoma In Situ: A Case Series. Khalfe Y; Rosen T J Drugs Dermatol; 2021 Feb; 20(2):169-171. PubMed ID: 33538561 [TBL] [Abstract][Full Text] [Related]
17. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. Jim On SC; Hashim PW; Nia JK; Lebwohl MG J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678 [TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP). Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145 [TBL] [Abstract][Full Text] [Related]
19. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487 [TBL] [Abstract][Full Text] [Related]
20. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. Bettencourt MS J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]